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Abstract Antibodies elicited by protein therapeutics can cause serious side effects in humans.
We studied immunogenicity of a recombinant fusion protein (FPX) consisting of two identical,
biologically active, peptides attached to human Fc fragment. EpiMatrix, an in silico epitopemapping tool, predicted promiscuous T-cell epitope(s) within the 14-amino-acid carboxyterminal region of the peptide portion of FPX. On administration of FPX in 76 healthy human
subjects, 37% developed antibodies after a single injection. A memory T-cell response against the
above carboxy-terminus of the peptide was observed in antibody-positive but not in antibodynegative subjects. Promiscuity of the predicted T-cell epitope(s) was confirmed by representation of all common HLA alleles in antibody-positive subjects. As predicted by EpiMatrix, HLA
haplotype DRB1*0701/1501 was associated with the highest T-cell and antibody response. In
conclusion, in silico prediction can be successfully used to identify Class II restricted T-cell
epitopes within therapeutic proteins and predict immunogenicity thereof in humans.
© 2007 Published by Elsevier Inc.

Introduction
Virtually all therapeutic proteins induce some level of
antibody response. Protein-induced immune responses can
vary from low-level, low-affinity and transient IgM antibodies to high-level, high-affinity IgG antibodies. Antibodyrelated clinical sequelae also vary from none to severe, and
⁎ Corresponding author.
E-mail address: ifica99@yahoo.com (E. Koren).
1521-6616/$ – see front matter © 2007 Published by Elsevier Inc.
doi:10.1016/j.clim.2007.03.544

can occasionally be associated with life threatening side
effects [1]. Antibody analyses from a number of clinical
studies strongly suggest that serious side effects are
associated with high levels of IgG antibodies [2–6]. Such an
antibody response is T-lymphocyte driven and includes
isotype switching and affinity maturation [7]. T-helper
cells, a subset of T-lymphocytes that specifically recognize
epitopes presented by antigen presenting cells (APCs) in the
context of MHC (major histocompatibility complex) Class II
molecules, are the major drivers of the mature antibody
response. Protein therapeutics that express MHC Class II
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restricted T-helper epitopes are likely to elicit more frequent
and mature antibody responses with IgG as predominant
isotypes. These T-helper epitopes can be represented as
linear sequences comprising 8 to 12 contiguous amino acids
that fit into the MHC Class II binding groove. Over the last 10
years, a number of computer algorithms have been developed and used for detecting Class II epitopes within protein
molecules of various origins (De Groot and Berzofsky [8] and
the accompanying issue of Methods [9]). Such “in silico”
predictions of T-helper epitopes have already been successfully applied in attempts to increase immunogenicity and
efficacy of vaccines [10–12].
The relationship between T-cell epitopes and immune
response has also been the subject of a number of
investigations in the field of protein therapeutics. In some
cases, therapeutic proteins have also been screened for Thelper epitopes in an attempt to evaluate their potential
immunogenicity [13–16]. Obviously, reliable in silico prediction of helper epitopes would be of significant value in
development of protein therapeutics. Such predictions
would make it possible to meaningfully rank candidates at
the pre-clinical stage of drug development or to reengineer
proteins to make them less immunogenic. Furthermore,
individuals at higher risk of developing T-cell-driven antibody
responses to the protein therapeutic could be identified
prospectively using HLA (human leukocyte antigen) typing, if
certain HLA can be associated with T-cell response and higher
neutralizing antibody titers, as recently described by
Barbosa et al. [14]. The use of these methods in the context
of clinical trials of protein therapeutics is rather recent and
deserves further exploration.
In this study, we describe the in silico evaluation of a
protein therapeutic in terms of its T-helper epitope content.
At the time of the epitope analysis, this protein had also been
administered to human subjects in a clinical trial. We were
therefore, able to test subsequent immune responses in vivo
and compare them with the EpiMatrix predictions of
immunogenicity.

Materials and methods
Human fusion protein
A recombinant human fusion protein (FPX) consisting of a
human Fc fragment fused with two identical 24-amino-acid
peptides was generated as described previously [17]. Briefly,
phage display peptide libraries (Dyax Corp.) were employed
and panned against the targets. After several rounds of
selection, the resulting target specific-binding clones were
recovered and converted into peptide-Fc fusion proteins (by
expressing the active peptides in Escherichia coli as fusions
to the Fc portion of human IgG1). One of the peptide-Fc
fusion proteins (termed FPX) with two identical 24-aminoacid peptides attached to the amino-terminal end of the
human germ line Fc-γ fragment was chosen for the study.

Generation of FPX peptide fragments
Solid-phase peptide synthesis
In addition to the whole fusion protein, three peptides
spanning amino acids 1–10 (aa 1–10), 11–24 (aa 11–24) and
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1–24 (aa 1–24) of the FPX peptide portion were synthesized.
These peptide fragments were prepared at 0.2-mmol scale
on a Symphony peptide synthesizer (Protein Technologies
Inc., Tucson, AZ) or Odessey peptide synthesizer (CEM,
Matthews, NC) employing Fmoc/OtBu protection strategy.
All Fmoc amino acids were purchased from Midwest Biotech
(Fishers, IN). Preloaded Fmoc-Glu (OtBu), Fmoc-Trp (Boc),
Fmoc-Pro, Fmoc-Leu HMP resins were purchased from Midwest Biotech (Fishers, IN).
Purification
Crude peptide and HPLC pooled fractions were analyzed by
analytical RP-HPLC with a Vydac (Hesperia, CA) 214TP™ C18
column using linear gradients of 0–60% ACN in 0.1% aqueous
TFA over 30 min, and a flow rate of 0.6 ml/min. The largescale RP-HPLC was carried out with a Vydac 218TP C18
column (Vydac) by using a linear gradient of 5 to 40% ACN in
0.1% aqueous TFA over 50 min with a flow rate of 20 ml/min.
Mass spectral analysis
HPLC-MS was performed with an API 150 (PerSeptive
Biosystems) in conjunction with Waters analytical HPLC
system (Waters Corporation, Milford, MA) by using YMC ODSAQ C18 column, with a linear gradient of 0% to 60% ACN in
0.1% aqueous TFA over 12 min with a flow rate of 0.6 ml/min.

Human subjects and FPX dosing
The primary objective of this study was to assess the safety
and tolerability of FPX. The study included standard safety
monitoring (e.g., collection of adverse experience reports;
repeated clinical chemistry, hematology, urinalysis, electrocardiograms and other assessments typical for this stage of
development) as well as assessment of the pharmacokinetic
properties of FPX. Healthy human female and male subjects
were dosed with FPX in a Phase 1, single dose, and placebocontrolled, randomized, blinded, sequential dose escalation
study. All subjects provided informed consent for participation in the study including HLA typing, anti-FPX antibody
assays and T-cell assays. The study enrolled 76 subjects aged
18 to 55 years. In total, 36 subjects received a single dose of
FPX intravenously and 40 subjects received FPX subcutaneously. Blood samples for analysis of anti-FPX antibodies
were collected from all subjects on day 1 prior to dosing and
on day 42 after dosing. In addition, eleven antibody-positive
and 4 antibody-negative subjects agreed to provide additional blood samples for the in vitro PBMC studies with the
FPX peptide fragments and HLA typing at the 6 months
follow-up visit.

Prediction and characterization of T-helper epitopes
The peptide portion of the FPX fusion protein (FPX peptide)
was screened for potential immunogenicity using previously
published EpiMatrix System [18,19]. Briefly, the 24-aminoacid sequence was parsed into overlapping 9-mer frames
where each frame overlaps the last by eight amino acids. Each
frame was then scored for predicted binding to each of eight
common Class II HLA alleles (DRB1*0101, DRB1*0301,
DRB1*0401, DRB1*0701, DRB1*0801, DRB1*1101, DRB1*1301,
and DRB1*1501). Due to their prevalence and their difference
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from each other, these eight alleles cover around 97% of
human populations worldwide [20].
EpiMatrix raw binding score predicted for each 9-mer
sequence was normalized with respect to a distribution of
scores derived from a very large set (N N 10,000) of randomly
generated 9-mer sequences. This results in a “Z” score for
each analyzed 9-mer. The Z score determines the position of a
9-mer relative to the distribution of all binding scores
generated for the random 9-mer sequences. Any peptide
scoring above 1.64 on the EpiMatrix “Z” scale (approximately
the top 5% of the random peptide set) has a significant chance
of binding to the MHC molecule for which it was predicted.
Peptides scoring above 2.32 on the scale (the top 1%) are
extremely likely to bind; most published T-cell epitopes fall
within this range of scores. Therefore, the higher the Z score,
the higher is the probability that a peptide will be presented
to T-cells by the antigen presenting cells (APCs). Previous
studies have demonstrated that EpiMatrix accurately predicts
published MHC ligands and T-cell epitopes [21–23].

Antibody detection and characterization
Antibody detection
Antibodies directed against FPX were detected using a
validated surface plasmon resonance (SPR)-based biosensor
immunoassay using the Biacore 3000™ instrument (Biacore,
Inc., Uppsala, Sweden) as previously described [24,25]. In
brief, FPX peptide was covalently immobilized onto the flow
cell of a CM-5 sensor chip using standard amine coupling
chemistry. Human serum samples were injected across the
FPX surface followed by the goat anti-human IgG F(ab′)2
antibody to confirm the antibody nature of the material
bound to the FPX surface. The change in the SPR signal
resulting from the bound human antibody and anti-human
secondary antibody was reported in relative response units
(RU). Serum samples were reported “reactive” for anti-FPX
antibodies if the combined sample and confirmatory antibody binding (in RU) was greater than or equal to the
validated threshold value (in RU). Samples below this
threshold value were reported antibody-negative. All “reactive” samples were reported as positive if the combined
sample and confirmatory binding of the post-dose sample
was at least 2-fold greater than the combined sample and
confirmatory binding of the pre-dose sample.
Antibody characterization
Serum samples from eleven antibody-positive (5 IV and 6 SC
dosed) subjects who agreed to provide additional blood
samples for the in vitro T-lymphocyte studies with the FPX
peptide fragments and HLA typing were characterized to
determine the antibody isotype.
Relative antibody concentration
A rabbit polyclonal affinity-purified anti-FPX antibody (prepared at Amgen) was spiked into normal human serum and
serially diluted to achieve calibrator concentrations ranging
from 0.2 to 50 μg/ml. The binding of each calibrator to the
immobilized FPX was analyzed as described, expressed in RUs
and plotted against the antibody concentration. The relative
antibody concentration for each clinical sample was extrapolated from the calibrator curve and expressed in μg/ml of
anti-FPX antibody. The limit of detection of this assay was
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validated at 800 ng/ml of anti-FPX antibodies in neat human
serum. Concentrations below 800 ng/ml were not detectable
due to the background observed in drug-naive normal human
sera.
Antibody isotype determination
The commercial (ICN Biomedicals; anti-human IgG, 8029-FICN; anti-human IgM M2110168; anti-human IgE, 8646F-ICN;
anti-human IgA, 8647-F-ICN) isotype reagents were used.
Each clinical sample was injected across the immobilized
peptide portion of FPX on the sensor chip followed by the
sequential injection of the anti-IgA, IgE, IgM and then the IgG
antibody. Report points were taken before and after each
injection and the difference was recorded in relative RUs.
Binding of each isotype-specific reagent (in RU) greater than
100 RU from the RUs recorded after sample binding, was
reported as positive for the qualitative identification of the
specific antibody isotype.

HLA typing
HLA typing was carried out by the National Histocompatability Laboratory division of the American Red Cross using
IsoCards according to the protocol supplied by the Red Cross.
Thirty to forty microliters of blood was obtained from each
subject by finger prick. Blood samples were placed on the
IsoCard using a pipette. The samples were then allowed to air
dry and individually sealed in plastic bags. Each sample was
then shipped to the American Red Cross (National Histocompatibility Laboratory at the University of Maryland Medical
System) for processing and HLA typing.

ELISPOT assays
Peripheral blood mononuclear cells (PBMC) were isolated
from FPX-treated subjects' heparinized peripheral blood
samples by Ficoll separation and cryopreserved in 10% DMSO
(dimethyl sulfoxide) in liquid nitrogen. For the assay, the
PBMCs were quickly thawed at 37 °C, diluted in 15 ml of RPMI
supplemented with 10% heat-inactivated human serum
(Valley Biomedical), spun at 300×g for 20 min, decanted,
and resuspended in RPMI supplemented with 10% heatinactivated human serum. The cells were then plated at
1 × 107 cells/well in a 12-well tissue culture dish (Corning)
and placed in a 37 °C incubator with 5% CO2. After 24 h,
10 μg/ml of the study peptides was added to the wells. PHA
(10 μg/ml) was added to positive control and the culture
medium to the negative control wells. On Day 2, 10 U/ml IL-2
and 20 ng/ml IL-7 (R&D Systems) were added to each of the
wells. Cells were incubated for 7 days, with half the media
being replaced on Day 4 with fresh media containing the
interleukins.
On Day 7, the PBMCs were harvested and plated at 2 × 105
cells per well in separate ELISPOT plates pre-coated with
monoclonal antibodies to INF-γ and IL-4 respectively
(MabTech). Target peptide was added to each test well at
10 μg/ml and the final volume was adjusted with medium
to 200 μl/well. This was followed by the 48-h incubation
at 37 °C and 5% CO2. Positive control wells treated with
10 μg/ml PHA and negative controls with 10 μl PBS were
incubated under identical conditions. Cells were discarded
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EpiMatrix Z scores for 9-mer sequences of the peptide portion of the FPX molecule

after the incubation and plates were washed with 0.05%
PBST, incubated with HRP-conjugated mouse polyclonal
anti-human INF-γ or mouse anti-human IL-4 secondary
antibody for 2 h at room temperature, washed with PBS
and developed by the addition of the TMB substrate. After
15 min, plates were washed with de-ionized water and
allowed to air dry. The plates were subsequently screened
for spot forming cells (SFC) by a Zeiss automated spot
counter (Zellnet). Final results were expressed in terms of
ratios between the numbers of SFCs in wells incubated with
peptides or PHA and those counted in the negative control
wells containing PBS.

Statistical analysis
Differences between the cytokine SFC ratios were tested by
Wilcoxon's Exact test.

Blinding of laboratory personnel to clinical data
All four major components of this study were carried out in
three different laboratories in a completely blinded fashion.
EpiVax staff conducted in silico epitope prediction as well as
in vitro PBMC challenge tests with no knowledge of the
antibody or the HLA results. Similarly, HLA typing at the Red
Cross laboratory and antibody analysis at Amgen's Clinical
Immunology laboratory were also performed by personnel
who were blinded to the results of the epitope prediction and
PBMC testing results until the end of the study.

Results
Prediction of T-cell helper epitopes
The complete 24-amino-acid sequence of the FPX peptide
was screened for predicted immunogenicity using EpiMatrix.

As described above, the peptide sequence was parsed into
overlapping 9-mer frames and each frame was screened
against EpiMatrix matrices developed for a panel of eight of
the most common Class II HLA alleles. In total, 128 frameby-allele assessments were performed. Results of the
EpiMatrix analysis are shown in Table 1. Overall, 17 allelespecific 9-mer frames showed EpiMatrix Z scores above the
predetermined cutoff value of 1.64 (positive EpiMatrix
scores). Eleven of the positive frame-by-allele scores fell
within the top 5% of the Z score distribution established
for the random peptides and 6 scored above 2.32, which
placed them in the top 1% range of the Z score distribution.
All of these 6 highly scoring frames were located in the
carboxy-terminal region of the peptide comprising amino
acids 11–23.
Furthermore, the carboxy-terminal region (aa 11–23)
scored highly (Z N 2.32) with five separate HLA alleles
(DRB1*0701, *1501, *0101, *1301, *1101), suggesting that
this peptide had a significant potential to be presented by
five different HLA molecules to T-cells. This pattern is
characteristic of promiscuous epitopes that are immunogenic for a broad cross-section of individuals in any human
population [20].

Antibodies in subjects dosed with FPX
Thirty seven percent of all subjects developed detectable
antibodies after a single injection of FPX. The incidence of
40% was somewhat higher in SC-dosed subjects compared to
the 33% observed in IV-dosed subjects. Both IV and SC
subjects showed similar ranges of antibody concentrations
(∼ 5 to 20 and ∼ 4 to 19 μg/ml respectively). Based on
analyses of eleven antibody-positive subjects (5 IV and 6 SC
dosed) who agreed to provide additional blood samples for
the antibody characterization and in vitro lymphocyte
studies, all of these subjects' antibodies were of the IgG
isotype.
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Table 2 HLA DRB1⁎ haplotypes, antibody levels and in vitro secretion of IFN-γ and IL-4 by PBMCs of antibody positive and
antibody negative subjects dosed with FPX
Subject
ID

HLA DRB1⁎

Antibody
concentration
(μg/ml)

aa 1–10
INF-γ

aa 11–24
IL-4

SFC ratio
1038
1128
1163
1060
1148
1109
1070
1122
1153
1120
1131
1136
1034
1031
1138

0701/1501
0101/1301
0101/1701
0405/0101
0301/0701
0301/1101
0101/0103
0101/1401
0401
1104/1503
0404/1501
0102/0301
0101/1501
0301
0401/1101

20.20
1.50
1.03
1.11
5.60
1.20
2.80
1.14
1.80
0.82
2.70
n/a
n/a
n/a
n/a

1.88
1.50
0.66
1.35
1.16
1.68
1.16
1.15
1.03
1.01
1.45
0.81
1.34
0.82
1.22

INF-γ

aa 1–24
IL-4

SFC ratio
0.79
1.75
1.36
1.23
0.88
1.53
0.52
1.18
1.09
1.46
–
0.74
1.10
1.18
1.05

26.00
9.90
14.60
6.00
1.74
2.70
2.00
1.10
0.76
1.11
1.50
1.45
1.47
1.04
1.07

INF-γ

IL-4

SFC ratio
89.00
4.70

6.80
4.68

2.60
1.60
3.34
2.40
0.83
1.70
–
1.20
1.70
1.30
1.40

34.52
26.61
16.80
9.41
2.44
6.60
1.67
1.53
7.01

1.23
1.70
1.80
2.20
0.98
1.55

92.40
30.10
14.50
7.06
3.90
2.62
1.96
3.15
1.18
1.62
–
0.84
1.20
1.30
1.43

INF-γ and IL-4 values represent ratios between peptide-induced SFC and negative control SFC (spot forming cells).
Average SFC ratio for the PHA stimulated positive control = 10.
n/a = Not applicable in antibody negative subjects.

Secretion of cytokines by PBMCs incubated with test
peptides
Peptides aa 1–10, aa 11–24 and aa 1–24 were tested in the
interferon-gamma and IL-4 ELISPOT assays. Interferongamma and IL-4 SFC ratios for all three peptides were low
in antibody-negative subjects, ranging from 0.74 to 2.20.
The amino-terminal peptide aa 1–10 did not stimulate PBMCs
from the antibody-positive subjects either, judged by the low
interferon-gamma (0.66–1.88) and IL-4 (0.52–1.75) SFC
ratios (Table 2). These low aa 1–10 SFC ratios in the
antibody-positive subjects were not significantly different
from those observed in the antibody-negative subjects.
However, the carboxy-terminal peptide aa 11–24 caused
significant stimulation of PBMCs from antibody-positive
subjects judged by the secretion of both interferon-gamma
and IL-4. The interferon-gamma SFC ratios in the antibodypositive subjects ranged from 0.76 to 26.00 whereas the IL4
SFC ratios ranged from 0.83 to 89.00. The whole aa 1–24
peptide also stimulated secretion of both interferon-gamma
and IL4 in antibody-positive subjects. The interferon-gamma
SFC ratios ranged from 1.53 to 34.52 and the IL4 ratios
ranged from 1.18 to 92.40 (Table 2). These aa 11–24 and
aa 1–24 interferon-gamma and IL4 SFC ratios observed in
antibody-positive subjects were significantly higher
(P b 0.05) from their respective counterparts observed in
antibody-negative subjects.
Individual HLA haplotypes, antibody level and cytokine
SFC ratios for all three peptides are summarized for antibodypositive and antibody-negative subjects in Table 2. All HLA
alleles represented in the EpiMatrix epitope prediction panel
except DRB1*0801 were found in various combinations in 15
tested subjects. In addition, 7 new alleles (DRB1*1104, *1503,
*0404, *0103, *0405, *1701 and *1401) were found between
antibody-positive and 2 (DRB1*0102) among antibody-nega-

tive subjects (Table 2). A more pronounced PBMC responses to
both aa 11–24 and aa 1–24 peptides were observed in
subjects with haplotypes DRB1*0701/1501 in subject 1038
followed by *0101/1301 in subject 1128, *0101/1701 in
subject 1163 and 0405/0101 in subject 1060 in a descending
order. The haplotype DRB1*0701/1501 was associated not
only with the highest PBMC response but also with the highest
antibody level. A group of five antibody-positive subjects
with haplotypes *0301/0701 in subject 1148, *0301/1101 in
subject 1109, *0101/0103 in subject 1070, *0101/1401 in
subject 1122 and *0401 in subject 1153 showed a moderate to
low PBMC activation with peptides aa 11–24 and aa 1–24.
Finally, two antibody-positive subjects with haplotypes,
*1104/1503 in subject 1120 and *0404/1501 in subject 1131,
as well as all four antibody-negative subjects showed
virtually no PBMC activation with peptides aa 11–24 and
aa 1–24. The amino-terminal peptide aa 1–10 caused no
activation across the board irrespective of HLA haplotype or
antibody status (Table 2).

Discussion
This study describes immune responses to a recombinant Fc
fusion protein (FPX) in healthy human subjects. The FPX
molecule is a fusion molecule consisting of human germ line
Fcγ fragment and two identical, biologically active, 24amino-acid peptides which are attached to the aminoterminal end of the Fc fragment.
The 24-amino-acid peptide subunit of FPX was analyzed
for potential immunogenicity using the EpiMatrix computer
algorithm that predicts binding between the 9-mer peptide
sequences and eight common MHC Class II molecules and,
consequently, probability of such sequences to be presented
by APCs as T-cell helper epitopes. Overall, 17 allele-specific
9-mer frames showed EpiMatrix Z scores above the

Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein
predetermined cutoff value of 1.64 and 6 scored above 2.32,
which placed them in the top 1% range of the Z score
distribution. All of these 6 highly scoring frames were located
in the carboxy-terminal region of the peptide comprising
amino acids 11–23. Furthermore, the carboxy-terminal
region scored highly with five of eight common separate
HLA molecules suggesting that this peptide had the potential
to be presented by five different HLA molecules to T-cells.
This pattern is characteristic of promiscuous epitopes that
are immunogenic for a broad cross-section of individuals in
any human population [26].
The antibody response to FPX was consistent with high
immunogenicity predicted by EpiMatrix. Following a single
injection, 37% of dosed subjects developed anti-FPX antibodies. Subcutaneous administration resulted in somewhat
higher (40%) incidence of antibody response, when compared
to the IV dosing (33% of subjects). All subjects characterized
by isotyping were positive for IgG indicating that the
antibody response was T-cell-dependent and that isotype
switching had occurred. No other antibody isotypes were
detected. The association and dissociation profiles inferred
from the BIAcore sensorgrams demonstrated relatively fast
on- and slow off-rates in all characterized patients (data not
shown). Such a binding profile is characteristic of highaffinity antibodies, which further supports a mature T-celldriven antibody response.
In vitro PBMC activation by the FPX peptide and its
fragments was measured by the number of IFN-γ and IL-4
SFCs using ELISPOT assays. It has been established that
interferon-gamma and IL-4 SFCs observed using PBMCs, in
fact represent activation of CD-4+ T-helper lymphocytes
[27]. Both carboxy-terminal peptide aa 11–24 comprising
high scoring sequences (i.e., immunogenic peptide) and the
whole aa 1–24 peptide induced activation of PBMCs indicating the presence of peptide-specific memory T-lymphocytes
in the majority of antibody-positive subjects. Neither the
aa 11–24 nor aa 1–24 peptide induced PBMC activation in
antibody-negative subjects. The amino-terminal aa 1–10
peptide containing no positive EpiMatrix scoring sequences
(i.e., non-immunogenic peptide) induced no PBMC activation
in antibody-positive or antibody-negative subjects.
The antibody data demonstrating a strong T-cell-driven
response, as well as PBMC activation results provide
evidence that the in silico prediction of immunogenic T-cell
helper epitope(s) within the carboxy-terminal region of the
FPX peptide was correct. Furthermore, results of the HLA
typing confirmed the predicted promiscuity of carboxyterminal epitope(s), as all of the eight common HLA alleles
were found in antibody-positive subjects. It should be also
pointed out that the magnitude of the immune response
appeared to have been dependent on the HLA haplotype. For
example, subject 1038 who had the DRB1*0701 allele had the
highest antibody concentration as well as number of INF-γ
and IL4 SFCs. Another subject who had DRB1*0701 allele
(1148), also showed relatively high antibody concentration
with a lower, but measurable SFCs. The carboxy-terminal
region of the FPX peptide showed the highest EpiMatrix
binding score with the DRB1*0701 allele. In contrast, the
DRB1*0301 allele appeared to be associated with very low
EpiMatrix binding scores, negligible SFCs and a lack of an
antibody response. Barbosa et al. [14] have also discovered
an association between HLA DRB1*0701 allele and strong
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antibody response to recombinant beta-interferon. It should
be pointed out that antibody and PBMC samples were taken
at different time points in this study (i.e., Day 42 and
6 months respectively). This could have caused discrepancies
between antibody levels and T-cell responses observed in
some antibody-positive subjects. Combining epitope mapping with HLA haplotyping, as described in this study, may
also allow researchers to screen clinical cohorts for subjects
that are at higher risk for developing anti-drug antibodies.
This study also supports the precept that potential T-cell
epitopes are not randomly distributed throughout protein
sequences but instead tend to be clustered. These regions of
unusually high binding potential are called “T-cell epitope
clusters”. Epitope clusters range from 9 to roughly 25 amino
acids in length and, considering their affinity to multiple
alleles and across multiple frames, can contain anywhere
from 4 to 40 binding motifs [28]. It should be kept in mind
that an accurate assessment of the peptide binding potential
to the MHC Class II molecules represents only a part of an
accurate prediction of actual T-cell epitopes. The endosomes
and lysosomes of APCs host the processing and assembly
reactions that result in the display of peptides on MHC Class II
molecules [29]. It is conceivable that some peptides with the
high Class II binding potential will be actually presented by
APCs while others may never be displayed, depending on the
processing of a particular protein. It appears that the FPX,
with its two identical 24-amino-acid peptides attached to
the germ line Fcγ fragment was processed in a way that
resulted in effective presentation of the carboxy-terminal
aa 11–23 fragment comprising promiscuous T-cell epitope(s).
The T-cell-dependent antibody formation is one of the
most important mechanisms for induction of antibodies in
general [7]. In case of therapeutic proteins, two additional
immunogenic factors include inadvertent contamination of
the protein therapeutic with proinflammatory molecules and
formation of protein aggregates [30]. Therapeutic protein
manufacturers have developed methods for addressing the
latter mechanisms, including improved purification of the
recombinant protein and careful formulation of the therapeutic product. However, the first mechanism, which
involves interaction between the cellular and humoral
immune systems and the presentation of protein-derived
epitopes bound to HLA, remains a challenge in the development of therapeutic proteins.
This study demonstrates that epitope-mapping tools such
as EpiMatrix can be used to identify Class II restricted T-cell
epitopes contained within therapeutic proteins that have the
potential to drive an IgG response. Such in silico tools have the
potential to be applied at every stage of the protein
therapeutics pipeline from identification of lead candidates
to characterization of immunogenicity in clinical trials
participants. While more extensive validation is still needed,
this and a few other studies [14,16] indicate that T-cell epitope
prediction will be useful not only in vaccine development but
also in prospective engineering and re-engineering of protein
therapeutics, reducing the risk of immunogenicity and
improving the likelihood of success in clinical use.
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